Dear Editor: With the introduction of atypical antipsychotics, it was predicted that the incidence of hyperprolactinemia-induced infertility problems would decrease. However, the use of atypical antipsychotics during pregnancy is an area with more questions than answers. We present a case wherein clozapine therapy was continued successfully over 2 consecutive pregnancies.
Case Report
MK, aged 25 years and a housewife of rural background, was premorbidly well adjusted, with a family history of depression. She had an acute-onset 7-year continuous illness precipitated by the death of her father. The illness was characterized by auditory hallucinations (that is, commenting and commanding), tactile hallucinations, passivity phenomenon, aggression, negative symptoms, and disturbed biofunctions. There was no history suggestive of depression or mania, substance abuse, or head injury. During this period, treatment tolerance or resistance was seen with various antipsychotics (that is, chlorpromazine, haloperidol, trifluperazine, and risperidone). Hence, clozapine was initiated after baseline investigations up to 400 mg daily. With 8 months of treatment, significant improvement in psychopathology and functioning occurred, with associated weight gain of 10 kg. Over the next 3 years, clozapine was gradually reduced to 200 mg daily with no reemergence of positive symptoms but persistence of negative symptoms. MK was married in early 2001 and continued to take clozapine. She was informed about the risk of congenital malformations with antipsychotics and was advised to use contraception. However, she conceived after 6 months of marriage and continued with the pregnancy and with clozapine. Venereal Disease Research Laboratory Slide Test (VDRL), HIV, and hepatitis B surface antigen titers were negative during the first trimester, and there was no evidence of congenital malformations during antenatal ultrasonography on repeat occasions. Hemoglobin was 9.6 gram percent at the 10th week of pregnancy; folic acid and iron supplements were initiated at 10 and 16 weeks, respectively. Pregnancy-induced hypertension (PIH) was detected at the 38th week and was monitored. At the beginning of the 39th week, a 3-kg boy was delivered by episiotomy, with Apgar scores of 8 and 9 at 1 and 5 minutes, respectively. The postnatal period was uneventful, with normal developmental growth until age 20 months.
Eight months after the first delivery, the patient reconceived and continued the pregnancy while on clozapine 100 mg daily. PIH occurred at 30 weeks and was managed with methyldopate hydrochloride 1500 mg daily. At 39 weeks, a 2.8-kg girl in breech presentation was delivered by elective cesarean section. The baby's Apgar scores were 7 and 9 at 1 and 5 minutes, respectively, with no postnatal complications. Developmental status was normal until age 6 months.
Discussion
Clozapine is a "Category B" drug with no controlled studies in pregnant women. Available data are generally in the form of case reports or series (1) .
A recent review reported 5 congenital malformations and 5 perinatal syndromes in each of 61 children exposed to clozapine (1) . Various associations with maternal exposure include floppy infant syndrome (2), neonatal seizures (3), new onset or worsening of gestational diabetes mellitus with shoulder dystocia (4,5), decreased variability of fetal heart rate (6) , and intrauterine growth retardation with oligohydroamnios (7) . However, use of drugs concomitant with malnutrition and family history of diabetes mellitus have been certain confounding factors.
Conversely, Waldman and others reported at least 15 normal births with maternal clozapine exposure and have discounted definite association between clozapine and congenital malformations (4).
In the case of our patient, clozapine was not associated with any adverse effects on the fetus (including congenital malformations) over 2 consecutive pregnancies, which adds to clozapine's safety data and is in keeping with a recent suggestion that it may be justifiable to continue clozapine during pregnancy when benefits outweigh the risks (8) .
Revisiting the Diagnostic Challenges of Secondary Mania and Bipolar Disorder in a Patient With Borderline Hyperthyroidism
Dear Editor: It can be a challenge to differentiate between a manic episode in bipolar disorder (BD) and a manic episode owing to a general medical condition. There are few case reports of BD associated with hyperthyroidism, despite the fact that symptoms of a manic episode overlap with those of hyperthyroidism (1) (2) (3) (4) (5) (6) . This may be attributed to problems in establishing etiology because of past psychiatric history and previous treatment with lithium, which can have antithyroid effects (7) . There are few studies in the literature carried out with lithium-naive patients regarding thyroid dysfunction and BD (8) , and the role of a borderline hyperthyroid state in patients is not well described. Therefore, we report on a drugnaïve patient who presented with a manic episode and was found to have borderline hyperthyroidism.
Case Report
A woman, aged 54 years, presented at a university hospital with a 3-week history of elevated mood, grandiosity, incessant activity, and decreased sleep. There was no psychiatric history, and she had otherwise been functioning well. Her medical and family histories were unremarkable, and she was not on any medications. Her mental status exam revealed pressured speech and flight of ideas. On admission, her thyroid profile revealed the following: thyroid-stimulating hormone (TSH) 0.11 mU/L (0.35 to 5.5), free triiodothyronine (T3) 5.2 (3.5 to 6.5), free thyroxine (T4) 18 (11 to 23), and thyroglobulin 25.5 (< 43). Other routine blood tests and computed tomography imaging of her head were normal. Given the suppressed TSH, she was diagnosed with borderline hyperthyroidism.
While in hospital, the patient received olanzapine dissolvable 5 to 7.5 mg once daily, and her manic symptoms abated over a week-long hospital stay. After discharge, she did not continue taking medications. On follow-up a month later, the patient had resumed her usual activities and was euthymic. At this time, lab tests were done and showed a normal thyroid profile.
In the case of borderline hyperthyroidism, it may be difficult to establish whether the hyperthyroid state is the etiologic cause, a contributing factor to the manic episode, or simply comorbid with BD. In this case, it is reasonable to postulate that the hyperthyroid state contributed to the manic episode or precipitated a manic episode in a patient predisposed to BD. This is further supported by the fact that the patient's symptoms resolved without further medications and were coincident with normalization of her thyroid profile. This reinforces the concept that perturbations in the thyroid function may be tied to manic symptomatology. At this time, the patient's preliminary diagnosis is secondary mania, and longitudinal follow-up of her mood symptoms and thyroid function may lead to a more definitive diagnosis. If she had another manic episode without clinical or laboratory indicators of hyperthyroidism, primary BD would be the diagnosis. Notwithstanding the diagnostic dilemma, we suggest that monitoring TSH is appropriate for patients with BD. For patients with recurrent or poorly controlled manic symptoms, it may be informative to see whether the manic symptoms coincide with changes in thyroid function. In conclusion, this case underscores the importance of monitoring TSH in patients with manic episodes.
Dyslipidaemia and Psychiatric Patients
Dear Editor: Associations between atypical antipsychotics (ATPs), weight gain (1), and diabetes (2) have been reported, and links between some ATPs and dyslipidaemia, particularly elevated triglycerides, have been identified (3). Dyslipidaemia is a major contributor to cardiovascular disease and 36% of deaths (over 78 900) in Canada yearly are due to diseases of the circulatory system (4). Raised C-reactive protein is also seen as a strong predictor of a cardiovascular event (5) .
Nine months ago, I began routinely testing patients' lipid, C-reactive protein, and blood glucose levels. So far, I have tested 89 patients, about one-sixth of my practice. Among those patients tested, 67% had a two-fold or more risk of a cardiovascular event, based on a raised total cholesterol/HDL-C ratio. This held true whether the patient was on a conventional antipsychotic, (11 of 13 or 85%) , an ATP (25 of 41or 61%, or no antipsychotic (25 of 35 or 66%). Elevated C-reactive protein was present in 8% of patients. The screening process did not allow for any attribution of cause or determination of how long the elevated levels had been present.
Monitoring weight, blood glucose, and lipids should become routine psychiatric practice, and where necessary, the primary physician should be alerted. These measures are not routinely done in psychiatric inpatient settings, and a recent survey found that only about 50% of inpatients were checked for blood glucose and weight (6) . Encouraging healthy diets, weight loss, and exercise is necessary. However, results of exercise programs may not be encouraging, as motivation is crucial (7) . Medical management, including the use of statins, may be indicated.
If my results are characteristic of a general adult psychiatric population, all patients, regardless of diagnosis and treatment, should be appropriately screened and monitored. Psychiatric populations, for various reasons, appear to be at increased risk of cardiovascular disease.
